GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poniard Pharmaceuticals Inc (OTCPK:PARD) » Definitions » ROC %

Poniard Pharmaceuticals (Poniard Pharmaceuticals) ROC % : -265.84% (As of Sep. 2011)


View and export this data going back to 2012. Start your Free Trial

What is Poniard Pharmaceuticals ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Poniard Pharmaceuticals's annualized return on capital (ROC %) for the quarter that ended in Sep. 2011 was -265.84%.

As of today (2024-04-29), Poniard Pharmaceuticals's WACC % is 0.00%. Poniard Pharmaceuticals's ROC % is 0.00% (calculated using TTM income statement data). Poniard Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Poniard Pharmaceuticals ROC % Historical Data

The historical data trend for Poniard Pharmaceuticals's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Poniard Pharmaceuticals ROC % Chart

Poniard Pharmaceuticals Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -131.10 -181.28 -292.02 -233.19 -229.26

Poniard Pharmaceuticals Quarterly Data
Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -160.34 -178.78 -206.25 -257.91 -265.84

Poniard Pharmaceuticals ROC % Calculation

Poniard Pharmaceuticals's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2010 is calculated as:

ROC % (A: Dec. 2010 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2009 ) + Invested Capital (A: Dec. 2010 ))/ count )
=-26.332 * ( 1 - % )/( (16.545 + 6.426)/ 2 )
=-26.332/11.4855
=-229.26 %

where

Poniard Pharmaceuticals's annualized Return on Capital (ROC %) for the quarter that ended in Sep. 2011 is calculated as:

ROC % (Q: Sep. 2011 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2011 ) + Invested Capital (Q: Sep. 2011 ))/ count )
=-14.992 * ( 1 - % )/( (5.795 + 5.484)/ 2 )
=-14.992/5.6395
=-265.84 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2011) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Poniard Pharmaceuticals  (OTCPK:PARD) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Poniard Pharmaceuticals's WACC % is 0.00%. Poniard Pharmaceuticals's ROC % is 0.00% (calculated using TTM income statement data). Poniard Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Poniard Pharmaceuticals ROC % Related Terms

Thank you for viewing the detailed overview of Poniard Pharmaceuticals's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Poniard Pharmaceuticals (Poniard Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
300 Elliott Avenue West, Suite 530, Seattle, CA, USA, 98119
Poniard Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of cancer therapeutics. Its product candidate is picoplatin, a new generation platinum-based cancer therapy.
Executives
Michael S Perry officer: President & CMO C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155
Ron Martell director, officer: Chief Executive Officer PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Gary A Lyons director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
David R Stevens director 300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114
Gerald Phd Mcmahon director 300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114
Carl Goldfischer director 161 WEST 61ST STREET, NEW YORK NY 10022
Fred B Craves director 750 BATTERY ST, STE 600, SAN FRANCISCO CA 94111
Simon Nicholas J Iii director, 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Gregory L Weaver officer: Chief Financial Officer 185 BERRY STREET, SUITE 6504, SAN FRANCISCO CA 94107
Kurt Wheeler 10 percent owner 801 GATEWAY BLVD, STE 410, SAN FRANCISCO CA 94080
Mpm Asset Management Investors 2005 Bviii Llc 10 percent owner C/O MPM ASSET MANAGEMENT, 111 HUNTINGTON AVENUE 31ST FLOOR, BOSTON MA 02199
Nicholas Galakatos 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Dennis Henner 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Michael Steinmetz 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Luke Evnin 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH STREET, BOSTON MA 02116

Poniard Pharmaceuticals (Poniard Pharmaceuticals) Headlines